Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Eduardo Davila

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-0817

    Collapse Research 
    Collapse research activities and funding
    R01CA140917     (DAVILA, EDUARDO)Jun 1, 2009 - May 31, 2015
    NIH
    TLR2 Engagement on Tumor-Specific T Cells: Mechanisms of Costimulation
    Role: Principal Investigator

    R01CA166961     (RAPOPORT, AARON P)Sep 1, 2012 - Aug 31, 2017
    NIH
    Adoptive transfer of gene-modified autologous T-cells post-ASCT for myeloma
    Role: Co-Principal Investigator

    I01BX002142     (DAVILA, EDUARDO)Jan 1, 2015 - Dec 31, 2019
    NIH
    IL-1 Receptor-Associated Kinase as a Cancer Therapeutic Target
    Role: Principal Investigator

    R25GM113262     (CAREY, GREGORY B)Mar 1, 2016 - Feb 28, 2026
    NIH
    UMB Postbaccalaureate Research Education Program
    Role: Co-Principal Investigator

    R01CA207913     (DAVILA, EDUARDO)Apr 1, 2017 - Aug 31, 2018
    NIH
    Augmenting T cell activity to weak tumor antigens and reversing myeloid cell-mediated T cell inhibition
    Role: Principal Investigator

    T32CA236734     (JIMENO, ANTONIO)Jul 8, 2019 - Jun 30, 2024
    NIH
    Cancer Immunotherapy and Experimental Therapeutics - T32
    Role: Co-Principal Investigator

    I01BX004935     (DAVILA, EDUARDO)Apr 1, 2020 - Mar 31, 2024
    NIH
    Restoring the Regulation of a Central Signaling Pathway to Prevent Metastases and Reinstate Tumor Immunity
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Marín-Jiménez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, Barkow JC, Geng D, Kar A, Yingst A, Tufa DM, Dolan JT, Blatchford PJ, Freed BM, Torres RM, Davila E, Slansky JE, Pelanda R, Eckhardt SG, Messersmith WA, Diamond JR, Lieu CH, Verneris MR, Wang JH, Kiseljak-Vassiliades K, Pitts TM, Lang J. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Front Immunol. 2021; 12:607282. PMID: 33854497.
      View in: PubMed
    2. Younis RH, Ghita I, Elnaggar M, Chaisuparat R, Theofilou VI, Dyalram D, Ord RA, Davila E, Tallon LJ, Papadimitriou JC, Webb TJ, Bentzen SM, Lubek JE. Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile. Front Immunol. 2021; 12:596646. PMID: 33776991.
      View in: PubMed
    3. Ciavattone NG, Wu L, O'Neill R, Qiu J, Davila E, Cao X. MyD88 Costimulation in Donor CD8+ T Cells Enhances the Graft-versus-Tumor Effect in Murine Hematopoietic Cell Transplantation. J Immunol. 2021 Feb 15; 206(4):892-903. PMID: 33408257.
      View in: PubMed
    4. Geng D, Ciavattone N, Lasola JJ, Shrestha R, Sanchez A, Guo J, Vlk A, Younis R, Wang L, Brown AJ, Zhang Y, Velasco-Gonzalez C, Tan AC, Davila E. Induction of IRAK-M in melanoma induces caspase-3 dependent apoptosis by reducing TRAF6 and calpastatin levels. Commun Biol. 2020 Jun 12; 3(1):306. PMID: 32533049.
      View in: PubMed
    5. Guo J, Muse E, Christians AJ, Swanson SJ, Davila E. An Anticancer Drug Cocktail of Three Kinase Inhibitors Improved Response to a Dendritic Cell-Based Cancer Vaccine. Cancer Immunol Res. 2019 09; 7(9):1523-1534. PMID: 31266784.
      View in: PubMed
    6. Kaczanowska S, Joseph AM, Guo J, Tsai AK, Lasola JJ, Younger K, Zhang Y, Gonzales CV, Davila E. A Synthetic CD8a:MyD88 Coreceptor Enhances CD8+ T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens. Cancer Res. 2017 12 15; 77(24):7049-7058. PMID: 29055013.
      View in: PubMed
    7. Tsai AK, Khan AY, Worgo CE, Wang LL, Liang Y, Davila E. A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies. Cancer Immunol Res. 2017 09; 5(9):790-803. PMID: 28775208.
      View in: PubMed
    8. Geng D, Kaczanowska S, Tsai A, Younger K, Ochoa A, Rapoport AP, Ostrand-Rosenberg S, Davila E. TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. Cancer Res. 2015 May 15; 75(10):1959-1971. PMID: 25795705.
      View in: PubMed
    9. Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph MA, McKenna C, Bansal N, Ochoa A, Davila E. Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res. 2012 Dec 01; 72(23):6209-16. PMID: 23041547.
      View in: PubMed
    10. Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, Davila E. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012 Dec 01; 18(23):6436-45. PMID: 23032741.
      View in: PubMed
    11. Sakoda Y, Park JJ, Zhao Y, Kuramasu A, Geng D, Liu Y, Davila E, Tamada K. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway. Blood. 2011 Feb 24; 117(8):2506-14. PMID: 21220749.
      View in: PubMed
    12. Geng D, Zheng L, Srivastava R, Velasco-Gonzalez C, Riker A, Markovic SN, Davila E. Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res. 2010 Oct 01; 70(19):7442-54. PMID: 20807806.
      View in: PubMed
    13. Geng D, Zheng L, Srivastava R, Asprodites N, Velasco-Gonzalez C, Davila E. When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood. 2010 Nov 04; 116(18):3494-504. PMID: 20696947.
      View in: PubMed
    14. Asprodites N, Zheng L, Geng D, Velasco-Gonzalez C, Sanchez-Perez L, Davila E. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J. 2008 Oct; 22(10):3628-37. PMID: 18587008.
      View in: PubMed
    Davila's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)